Suppliers are running low on Hormone Replacement Therapy (HRT) as shortages become a serious concern.
The understanding is that the manufacturing companies are not experiencing an issue, but the issue comes as suppliers are running low on stocks.
Harrow Health Care is advising that pharmacies should contact the companies directly to obtain their stocks, rather than through their suppliers.
This is certainly true for Janssen, the suppliers of the Evorel patch range, which has been hit particularly hard.
This week we have seen a number of calls from women in relation to supplies.
The updates from the companies are as follows;
- Elleste oral range – This is slowly coming back, and the whole range is now theoretically available, but you may need to order
- Evorel range – There are serious problems with both Sequi and Conti – we are unable to get unless the pharmacy has old stock. Evorel 50 is currently limited and set to get worse
- Estradot – There limited supplies only of most doses, available to order sometimes
- Elleste MX – We are currently unsure as to the stocks of this
This means we must consider what we recommend in the Harrow Health Care clinic. There is no point in suggesting a product that a GP then cannot follow up with.
In our experience, the following products are still in reasonable supply;
- Sandrena and Oestrogel
- Utrogestan
- Femoston range
- Novofem
- Kliovance and Kliofem
For advice in relation to the HRT shortages, speak to the expert team at Harrow Health Care today.
